Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • Corvus Pharmaceuticals' Accounts Payables rose 539.24% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 539.24%. This contributed to the annual value of $2.6 million for FY2024, which is 6931.15% up from last year.
  • Corvus Pharmaceuticals' Accounts Payables amounted to $2.0 million in Q3 2025, which was up 539.24% from $3.1 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Accounts Payables' 5-year high stood at $4.2 million during Q3 2022, with a 5-year trough of $1.2 million in Q2 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' median Accounts Payables value was $2.0 million (recorded in 2025), while the average stood at $2.1 million.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Accounts Payables crashed by 6678.5% in 2023 and then soared by 15861.5% in 2025.
  • Corvus Pharmaceuticals' Accounts Payables (Quarter) stood at $2.0 million in 2022, then dropped by 22.82% to $1.5 million in 2023, then skyrocketed by 69.31% to $2.6 million in 2024, then fell by 23.55% to $2.0 million in 2025.
  • Its Accounts Payables stands at $2.0 million for Q3 2025, versus $3.1 million for Q2 2025 and $1.3 million for Q1 2025.